Furthermore, miR-6402 can serve as a novel therapeutic agent for obesity and its associated metabolic complications by targeting Bmpr2 as a signalling regulator of adipogenesis, rather than commonly studied adipogenesis markers such as Pparg. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.